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Objectives:  At present, sufficient prognostic markers for prostate cancer (PCa) progression are still lacking,
in spite of thorough investigation. The aim of this study was to evaluate abnormalities of -catenin protein
expression, subcellular localization and determine its relation to different clinicopathological features and
disease free survival in prostate cancer patients.
Patients  and  methods:  Forty prostate cancer specimens, obtained from patients with different stages of
prostate cancer (83% stage IV) who underwent a radical prostatectomy or TURP flanked by 2006 and
2011, -catenin was determined by immuno-histochemistry (IHC). The membranous expression was semi-
quantitatively evaluated in four scores (0, 1+, 2+, 3+). Clinical records of these patients were studied for
follow up data.
Results:  -Catenin immune staining results show over-expression of -catenin in PCa Libyan patients.
There was no statistically significant difference in -catenin immune expression as regards histopathological
type, perineural invasion, tumor stage, biological recurrence. However, -catenin over-expression showed
significant correlation with old age (p < 0.014).
Conclusions:  We concluded that changes in expression and cell distribution of -catenin correlated with the
progression degree of prostate adenocarcinoma, signifying a role of this molecule as a marker of progression
and prognosis. Further investigations, on a larger and more heterogeneous population, should be carried outlts.to validate and extend our resu© 2017 Pan African Urological Surgeons Association. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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rostate cancer (PCa) is the second most common cause of cancer
nd the sixth leading cause of cancer deaths among men world-
ide with an estimated 899,000 new cases and 258,000 new deaths
n 2008. The global PCa burden is anticipated to grow to 1.7 mil-
ion new cases and 499,000 new deaths by 2030 basically due to
he growth and aging of the global population [1]. Recent statistics
eveal that PCa continues to remain the most commonly diagnosed
ethal malignancy in men in the United States with 1 out of 6 men
eveloping PCa and 1 out of 35 dying from it [2].
here are now more than 240,000 men in the United States diag-
osed with PCa each year [3], and 90% of PCa are clinically
ocalized and occult disease at time of diagnosis [4].
n patients with localized PCa, the 5-year survival approximates
00%; however, in patients in whom distant metastasis have
ccurred, the 5-year survival drops to 31% [5]. Like most other
olid malignancies, PCa can metastasize to distant organs such as
he liver, lungs and brain, but it has an extraordinarily high propen-
ity for metastasizing to the bone. In one autopsy study, ∼80% of
he men who had died from PCa possessed bone metastasis [6].
leason grade is one of the most widely used grading systems for
redicting the progression of PCa. A more aggressive disease is
ssociated with higher Gleason sum scores. Nevertheless, the patho-
ogical grade, serum Prostate Specific Antigen (PSA) value and
linical stage have some restrictions that hinder evaluation of the
rognosis of PCa, although the PSA level combined with the Glea-
on grading system is still considered the most reliable prognostic
arker [7,8]. Presently, adequate prognostic or predictive markers
or tumor progression are still deficient. However, some molecules
re involved in diverse processes such as cell proliferation, apo-
tosis, cellular adhesion, tumor suppression and cell cycle-related
actors have been linked to PCa outcome [9,10].
everal genes and signaling pathways have been implicated in PCa
nitiation and progression, such as p53, C-MYC, Nkx3.1, PTEN,
ndrogen receptor (AR), and Wnt/-catenin [11]. Wnt/-catenin
ignaling has been implicated in both normal prostate development
nd in PCa progression [12]. -Catenin forms part of the adher-
nt junction with E-cadherin and is also a component of canonical
nt signaling. However, the function of -catenin in human PCa
s unclear [13]. It has been observed that -catenin expression
nd localization change during human PCa progression. However,
esults are inconsistent. Several studies have seen an increase in
-catenin expression and nuclear localization in late stage cancer
amples, while others have reported a loss in nuclear expression in
dvanced tumors [14–18].
n the current study, we examined the expression of -catenin in
 series of Libyan PCa by IHC. We tried to determine its value as
redictive marker for metastatic potential. Additionally, the relation-
hip between this molecular marker and known prognostic factors
f serum PSA and Gleason grade was evaluated.
atients  and  methodslinicopathological  features  and  follow  up  data
rchival samples of 40 prostatic adenocarcinoma were examined
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athology Department, Faculty of Medicine, Benghazi University
etween January 2006 to December 2011 depending on accessibility
f representative paraffin blocks.
he patient’s clinical files were read in the hospital archives in order
o gather the appropriate clinical information and follow up data for
urrent study. For each patient, we obtained the following infor-
ation: age, histological diagnosis, grading, staging, pre-treatment
SA level, date of diagnosis, treatment, cause and date of death. All
atients were followed up until death or when last seen alive at their
linical visit (Dec-2012) with the mean followup time of 25 months
range: 6–72 months). The duration of follow-up was determined
or each patient from hospital and clinic charts.
linical stages were determined according to the International
nion against Cancer (UICC) classification of 2009. Clinical
taging routinely included abdominal and pelvic computerized
omography (CT), chest radiograph or thoracic CT, isotope bone
canning, and extended/extensive prostate biopsy, as described else-
here. PSA levels at diagnosis ranged between 0.1 and 500 ng/ml
mean: 113 ng/ml), and Gleason score at biopsy ranged between 6
nd 10.
 skilled pathologist confirmed all diagnosis, and the following
istopathological features were recorded which include; histolog-
cal type, histological grading determined in accordance with the
leason grading system, lymphovascular invasion, perineural inva-
ion. All tumors were classified using the histopathological criteria
f WHO classification. The key clinicopathological data of patients
re summarized in Table 1.
mmuno-histochemical  method
-Catenin  immunostaining
araffin embedded blocks of PCa have been obtained from pathol-
gy department archive. Sections were cut in sequence at 5 m for
mmune-histochemical staining. IHC analysis has been done using
he automatic system (Bench-Mark XT, Ventana Medical System,
nc., Tucson, Arizona, USA). This fully automated processing for
ar code labeled slides included baking of the slides, solvent free
eparaffinization, antigen retrieval in a cell conditioning buffer CC1
Mild: 36 min conditioning, and standard: 60 min conditioning),
ncubation with Mouse monoclonal anti--catenin antibody (clone:
, isotype: IgG1, Catalog no.: 760-4242 Ventana Medical Systems),
or 32 min at 37 ◦C. Application of ultra-view TM universal DAB has
een applied. Ultra view DAB includes: ultra-view universal HRP,
ltra view universal DAB inhibitor, ultra view universal DAB chro-
ogen, ultra view universal DAB H2O2, and ultra view universal
AB copper. Counterstaining with haematoxylin (2021) for 4 min,
nd post-counterstaining with bluing reagent (2037) for 4 min. After
taining, the sections were dehydrated in ethanol, cleared in xylene,
nd covered with Mountex and cover slips.
valuation  of  -catenin  staining
he assessment of staining was performed with a light micro-
cope at the magnification of ×40, blinded by the information on
umor grade, stage or clinical outcome. Membranous and cytoplas-
ic staining was evaluated separately. For cell membrane staining,
our categories were used, (+++, ++, +, 0), where 0: no expres-
ion, no detectable staining in <10% of the membrane, +: weak but
etectable discontinuous staining present in 10–39% of the mem-
rane, ++: moderate, clearly positive discontinuous staining present
n 40–90% of the membrane, and +++: intense continuous staining
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Table  1  Clinicopathological characteristics of the patients with PCa.
Characteristic No. of patients Percentage (%)
Age (years) ≥74 23 57.5
<74 17 42.5
Type of biopsy Core biopsy 31 77.5
TURP 8 20
Radical prostatectomy 1 2.5
Histopathological type Acinar adenocarcinoma 39 97.5
Ductal adenocarcinoma 1 2.5
Pre-treatment PSA level mean (range) 112 (0.1–500) –





Histological grade Grade II (5–7) 14 35
Grade III (8–10) 26 65
Perineural invasion Yes 9 22.5
No 31 77.5
Lympho/vascular invasion Yes 3 7.5
No 37 92.5
Clinical stage II–III 7 17.5
IV 33 82.5
Metastasis Yes 33 82.5
No 7 17.5
Site of distant metastasis Bone 29 87.87
Liver 2 6.06
Bone and others (lung, liver, pancreas) 2 6.06
Biological recurrence Yes 14 35
No 19 47.5
Unknown 7 17.5


















of the membrane creates a honeycomb pattern. The cytoplasmic
staining was also graded into four categories where 0: negative, no
detectable staining, +: weak, but detectable still staining, ++: mod-
erate, clearly positive but still weak, +++: heavy staining, intense.
The membrane index (MI) was calculated with both the intensity of
staining and fraction of positively-stained cells taken into account
using the following formula:
I =  0 ×  f0 +  1 ×  f1 +  2 ×  f2 +  3 ×  f3
where I is the staining index, f0–f3 are the fractions of the cells show-
ing a defined level of staining intensity (from 0 to 3). Theoretically,
the index could vary between 0 and 3 [19,20]. The reproducibil-
ity of the -catenin staining indices was tested twice by one of
the observers (AE) analyzing the sections, after a few days (intra-
observer variation).Statistical  analysis
Statistical analysis was performed using the SPSS
®
(SPSS, Inc.,







ges (SPSS for Windows, version 18.0.3 and STATA/SE 11.1).
requency tables were analyzed using the Chi-square test, with the
ikelihood ratio (LR) or Fisher’s exact test being used to assess the
ignificance of the correlation between the categorical variables.
ifferences in the means of continuous variables were analyzed
sing non-parametric tests (Mann–Whitney) or Kruskall–Wallis for
- and K-independent samples respectively. Analysis of variance
as only used to derive the mean values (and 95% CI) of each
ndividual stratum. Univariate survival analysis for the outcome
easure [disease-specific survival (DSS) and disease-free survival
DFS)] was based on the Kaplan–Meier method, with log-rank
Mantel–Cox) comparison test. In all tests, p < 0.05 was regarded
s statistically significant.
esults
xpression  patterns  of  -cateninhe expression pattern of -catenin was predominantly membra-
ous, in normal prostatic glands, hyperplastic prostatic glands and
n tumor area as well. The expression patterns of -catenin in
Ca lesions are illustrated in the following figures respectively
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Table  2  Expression of -catenin in Libyan PCa patients as related to clinicopathological data and disease outcome.
Features Number (%) -Catenin expression (%) p-Value
Below mean = 0 Above mean = 1
Age ≥74 18 (45) 5/19 (26.3) 13/21 (61.9) 0.024
<74 22 (55) 14/19 (73.7) 8/21 (38.1)
Type of biopsy TURP 31 (77.5) 14/19 (73.7) 17/21 (81.0) 0.55
Core biopsy 8 (20) 4/19 (21.1) 4/21 (19)
Radical prostatectomy 1 (2.5) 1/19 (2.5) 0 (0)
Diagnosis Acinar adenocarcinoma 39 (97.5) 19/19 (100) 20/21 (95.2) 0.525
Ductal adenocarcinoma 1 (2.5) 0 (0) 1/21 (4.8)
Histological grade Grade II 14 (35) 10/19 (52.6) 4/21 (19.0) 0.014
Grade III 26 (65) 9/19 (47.4) 17/21 (81)
Perineural invasion Yes 9 (22.5) 4/18 (22.2) 5/22 (22.7) 0.970
No 31 (77.5) 14/18 (77.8) 17/22 (77.3)
Lymphovascular invasion Yes 37 (92.5) 1/19 (5.3) 2/21 (9.5) 0.609
No 3 (7.5) 18/19 (94.7) 19/21 (90.5)
Metastasis Yes 33 (82.5) 15/19 (78.9) 18/21 (85.7) 0.574
No 7 (17.5) 4/19 (21.1) 3/21 (14.3)
Biological recurrence Yes 13 (40.6) 7/16 (43.75) 10/16 (62.5) 0.719




























































Status at the end point Alive 
Dead 
Fig. 1a–d). The mean value of -catenin staining index (MI) was
.5.
orrelation  of  -catenin  expression  with  clinicopathological
haracteristics
he distribution of -catenin expression in tumor sample in rela-
ion to clinicopathological characteristics is present in Table 2.
sing different cut-off points mean, median, 3-tier score (0 vs 1,
, 3), (0, 1 vs 2, 3) and (0, 1, 2, 3). An interesting finding in our
mmune-histochemical study, -catenin over-expression (membra-
ous) shows a significant correlation with the age (p < 0.024) in that
umors of old patients (≥74 years) (13/18) over-express -catenin
ore than tumors of young patients (<74 years) (8/22). Moreover,
ver-expression of -catenin (membranous) was also significantly
p < 0.014) associated with the higher grade (Gleason > 7) in that
leason score >7 cancers (17/26) showed higher expression of
-catenin compared to Gleason score = 5–7 PCa (4/14).
here was no statistically significant difference in -catenin immune
xpression as regards histopathological diagnosis, type of biopsy
core, TURP, radical prostatectomy), perineural invasion, lympho-
ascular invasion, tumor stage and recurrence.
iscussion
nt/-catenin signaling plays a fundamental role in controlling an
rray of cellular processes, such as the determination of cell fate,
ell proliferation, migration, and polarity, and the maintenance of
tem cells. Various studies have reported that changes in Wnt signal-
ng can lead to carcinogenesis and the progression of malignancies,
ncluding PCa [21–23]. In addition, some investigators have sug-
ested that Wnt/-catenin signaling and the AR play critical roles




6.4) 6/16 (37.5) 6/17 (35.3) 0.895
3.6) 10/16 (62.5) 11/17 (64.7)
he role of -catenin in prostate development is not known and
ts function in prostate cancer is not clearly defined [25]. Previous
tudies implicated -catenin in the pathogenesis of PCa because
t localizes in tumor-cell nuclei in 20–40% of castration resistant
rostate cancer (CRPC) specimens [15,26,27]. More recently, a fur-
her group reported that activation of Wnt/-catenin signaling is
nvolved in PCa initiation and progression in a mouse model [12,28].
ollectively, these findings imply that the Wnt canonical pathway
s implicated in the pathogenesis of a subgroup of advanced PCa.
t has been observed that -catenin expression and localization
hange during human PCa progression, however, results are incon-
istent [25]. Aberrant expression and localization of -catenin in
Ca are more common than predicted by Wnt pathway mutation
13,29]. Abnormal -catenin expression was found in 23% of tumor
amples from radical prostatectomy, and in 38% of CRPC samples,
nd correlates with high Gleason score [15]. However, the detection
f nuclear -catenin in hyperplasia and in advanced tumors sug-
ests that activation of Wnt/-catenin signaling has a role in the
remalignant stages of the disease and in the progression to CRPC
30].
n this study, we examined the expression and localization of
-catenin protein in a subset of PCa and a number of adjacent histo-
ogically normal and hyperplastic mucosa. The results showed that
 membranous staining pattern was well preserved in prostatic ade-
ocarcinomas without detectable nuclear immuno-reactivity. This
nding is consistent with those of previous studies in which no
uclear -catenin immuno-staining was observed in prostatic ade-
ocarcinomas [14,31].n interesting finding in our immuno-histochemical studies is
hat the membranous over-expression of -catenin staining occurs
ainly in cases with higher Gleason scores (>7) prostatic adeno-
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Figure  1  (a) Immunohistochemical staining of -catenin. Membranous expression of -catenin in bening prostatic hyperplasia (IHCX20) (Depart-
ment of Pathology, Faculty of Medicine, Benghazi University). (b) Strong membranous -catenin expression in pattern three prostatic carcinoma













branous expression in some area of prostatic carcinoma (IHCX40) (Dep
membranous -catenin expression of prostatic carcinoma (IHCX 40) (D
carcinomas. This finding is consistent with finding of Whitaker
et al. who observed that increased -catenin expression in only high
Gleason score (>7) prostate cancer and a gradual loss in nuclear dis-
tribution with increasing Gleason grade [17]. The same observation
was established by Chen et al. who observed the high levels of Wnt-
1 and -catenin expression was linked with advanced, metastatic,
hormone-refractory prostate carcinoma, in which they can serve as
markers of disease progression [16]. On the other hand, Bismar
et al. and Kallakury et al. have found that the loss of -catenin was
associated with high tumor grade [32,33]. Even though, few stud-
ies [18,34] have reported that there was no signification association
between -catenin expression and Gleason score.
This discrepancies between our results and other might be explained
by the methodological differences in patient sampling, fixation and
the protocols used for immunohistochemical techniques.
In the current study, we did not find any significant correlation
between -catenin expression and lymphovascular invasion. A sim-
ilar finding has been reported by Morita et al. [14].
In conclusion we concluded that changes in expression and cell
distribution of -catenin correlated with the progression degree
of prostate adenocarcinoma, suggesting a role of this molecule as
marker of progression and prognosis, even if based on a restricted
number of cases. Admittedly, supplementary studies on a larger
cohorts and more heterogeneous population are necessary to validate
and extend our results.ent of Pathology, Faculty of Medicine, Benghazi University). (d) Weak
tment of Pathology, Faculty of Medicine, Benghazi University).
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